Endosomal Escape Pathways for Non-Viral Nucleic Acid Delivery Systems by Liang, Wanling & Lam, Jenny K.W.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 17 
 
 
 
 
© 2012 Liang and Lam, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Endosomal Escape Pathways  
for Non-Viral Nucleic Acid Delivery Systems 
Wanling Liang and Jenny K. W. Lam 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/46006 
1. Introduction 
Nucleic acids, including plasmid DNA (pDNA) and small interfering RNA (siRNA), are 
potential therapeutic macromolecules that have been widely explored for the treatment or 
prevention of various human diseases in the last three decades. pDNA encoding a 
therapeutic gene sequence can be introduced into the nuclei of the target cells to express 
functional proteins through transcription and translation in order to produce therapeutic 
effects. The therapeutic scope of pDNA includes a vast number of diseases, such as cancers 
(El-Aneed 2004; Yamamoto and Curiel 2005; Johnson, Morgan et al. 2009), genetic disorders 
(Gaspar, Parsley et al. 2004; Aiuti, Cattaneo et al. 2009; Griesenbach and Alton 2009), 
infections (Yu, Poeschla et al. 1994; Hashiba, Suzuki et al. 2001; Cull, Bartlett et al. 2002) and 
cardiovascular diseases (Stewart, Hilton et al. 2006; Vinge, Raake et al. 2008; Henry and 
Satran 2012). To date, over 1600 gene therapy clinical trials have been initiated 
(http://www.abedia.com/wiley/phases.php; Edelstein, Abedi et al. 2007). Apart from pDNA, 
siRNA has recently been intensively studied as a new therapeutic agent. RNA interference 
(RNAi) was discovered by Fire and colleagues based on the study of C. elegans (Fire, Xu et 
al. 1998). According to their observation, double-stranded RNA (dsRNA) mediates potent 
and specific silencing of homologous genes. Elbashir et al. demonstrated that the sequence-
specific mediator of RNAi is 21-23-nucleotide siRNA produced from the cleavage of longer 
dsRNA by ribonuclease III (Elbashir, Lendeckel et al. 2001). Since then the mechanism of 
RNAi has been revealed and reviewed in many publications (Bernstein, Caudy et al. 2001; 
Hammond, Boettcher et al. 2001; Ketting, Fischer et al. 2001; Hannon and Rossi 2004; Mello 
and Conte 2004). Briefly, siRNA interacts with the RNA-induced silencing complex (RISC) 
located in the cell cytoplasm and subsequently induces cleavage of mRNA with 
complementary sequences, thereby inhibiting the translation of a specific protein. Soon after 
RNAi was discovered to work in mammalian cells (Sui, Soohoo et al. 2002), it quickly 
emerged as a new therapeutic strategy to suppress the expression of disease-causing gene. 
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So far, the therapeutic potential of siRNA has been demonstrated successfully both in vitro 
and in vivo (Shim and Kwon 2010) while a number of siRNA-based therapy clinical trials 
have been initiated, including therapeutics directed against inherited skin disorder 
(Leachman, Hickerson et al. 2009), solid tumor (Davis, Zuckerman et al. 2010), respiratory 
syncytial virus (RSV) infection (DeVincenzo, Cehelsky et al. 2008; DeVincenzo, Lambkin-
Williams et al. 2010) and age-related macular degeneration (AMD) (Kaiser, Symons et al. 
2010). Until now however, there are no pDNA or siRNA-based therapeutic products 
approved by the FDA; the lack of an efficient and safe delivery system being the major 
hurdle to limit the clinical application of nucleic acids.  
1.1. Nucleic acid delivery 
In terms of delivery, therapeutic nucleic acids must be transported to their target sites 
(nucleus for pDNA or RISC in the cytoplasm for siRNA) before producing their biological 
effects. A delivery system must overcome a series of extracellular and intracellular barriers 
(Sanders, Rudolph et al. 2009). Nucleic acids are susceptible to endogenous nuclease 
degradation in the serum and the half-life of unprotected nucleic acids is approximately 10 
minutes in mouse whole blood (Kawabata, Takakura et al. 1995). In addition, nucleic acids 
are negatively charged, hydrophilic macromolecules and are incapable of crossing the 
plasma membrane unassisted (Khalil, Kogure et al. 2006; Lam, Liang et al. 2012). To achieve 
successful transfection, an effective nucleic acid delivery system must be able to perform 
several functions: (i) bind or condense nucleic acids into nanoparticles, (ii) protect nucleic 
acids from enzymatic degradation, (iii) promote cellular uptake, (iv) release nucleic acids 
into the cytoplasm, (v) promote nuclear entry (for pDNA delivery) (Bally, Harvie et al. 
1999). The use of a carrier system such as cationic polymers (Laga, Carlisle et al. 2012), 
lipids/ liposomes (Ewert, Zidovska et al. 2010) or peptides (Hassane, Saleh et al. 2010) is the 
most commonly investigated delivery method for clinical purposes. It was soon found that 
the transfection efficiency of nucleic acid delivery systems is correlated to not only the level 
of cellular uptake but also with their ability to escape from endosomal compartments (El 
Ouahabi, Thiry et al. 1997). Some nucleic acid delivery systems successfully attain high 
cellular uptake, but fail to achieve good transfection, partly due to their deficiency of 
endosomolytic property (Medina-Kauwe, Xie et al. 2005). Therefore additional measures 
must be adopted to promote endosomal escape of the nucleic acid delivery system.  
1.2. Intracellular delivery 
Viral vectors are known for their high efficiency in transferring nucleic acids into host cells 
as they have evolved sophisticated endosomal releasing mechanisms which take advantage 
of the acidic environment inside the endosomes (Cho, Kim et al. 2003). However, the clinical 
application of viral vectors is limited because of the strong immunogenicity and potential 
fatal adverse effects (Baum, Düllmann et al. 2003; Hacein-Bey-Abina, von Kalle et al. 2003; 
Raper, Chirmule et al. 2003; Hacein-Bey-Abina, Garrigue et al. 2008). Compared with viral 
vectors, non-viral vectors offer advantages of relatively low toxicity and immune response. 
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However, the delivery efficiency of non-viral vectors is generally poor (Pérez-Martínez, 
Guerra et al. 2011). To enhance transfection efficiency, substantial efforts have been made to 
elicit effective endosomal escape. Endocytosis is the major route of cellular entry for non-
viral nucleic acid delivery (Khalil, Kogure et al. 2006; Pathak, Patnaik et al. 2009). A number 
of endocytosis pathways are known to be involved in the uptake of non-viral gene delivery 
systems, including clathrin-mediated endocytosis, caveolae-mediated endocytosis, 
macropinocytosis and phagocytosis. However the contribution of each pathway in the 
internalization of non-viral vectors is not clearly understood due to the diversity of carriers 
(Morille, Passirani et al. 2008).  
After non-viral delivery systems enter into the cells via endocytosis they are immediately 
transported into the endocytic vesicles. Initially, the delivery vectors are trapped in the early 
endosomes where the pH drops from neutral to around pH 6. Early endosomes may fuse 
with sorting endosomes in which the internalized content can be recycled back to the 
membrane and transported out of the cell by exocytosis. More often, the delivery systems 
are trafficked to late endosomes which are rapidly acidified to pH 5–6 by the action of the 
membrane-bound ATPase proton-pump. Subsequently, the late endosomes fuse with 
lysosomes concomitant with a further pH reduction to approximately pH 4.5 and the 
existence of various degradative enzymes. The low pH of lysosomes facilitates substrate 
denaturation and aids lysosomal hydrolases, most of which operate optimally in the range 
of pH 4.5-5.5 (Mellman, Fuchs et al. 1986). Nucleic acids that fail to be released from these 
acidic vesicles will ultimately be degraded (Pack, Hoffman et al. 2005; Khalil, Kogure et al. 
2006). Therefore, the pH reduction and the enzymatic degradation process in 
endosomes/lysosomes is an efficiency-limiting step for successful nucleic acid delivery 
(Whitehead, Langer et al. 2009). Ideal vectors should release their contents from these acidic 
compartments at an early stage to prevent the fate of lysosomal destruction.  
1.3. Endosomal escape 
Various approaches have been attempted to promote early endosomal escape of non-viral 
gene delivery vehicles and many hypotheses have been suggested to explain these 
processes. The proton sponge hypothesis has been proposed for cationic polymers such as 
polyethylenimine (PEI) (Boussif, Lezoualc'h et al. 1995; Behr 1997) and polyamidoamine 
(PAMAM) dendrimers (Zhou, Wu et al. 2006). For cationic-lipid based delivery systems, the 
flip-flop mechanism was proposed for their endosomal escape mechanism (Xu and Szoka Jr 
1996). Cell-penetrating peptides (CPPs) represent another category of promising candidates 
as non-viral nucleic acid carriers, for example TAT (Torchilin 2008), pep analogues (Gros, 
Deshayes et al. 2006), GALA (Li, Nicol et al. 2004), MPG (Simeoni, Morris et al. 2003), CADY 
(Konate, Crombez et al. 2010) and LAH4 derivatives (Lam, Liang et al. 2012) etc. Their 
mechanisms of promoting endosomal release are still controversial; it has been suggested 
that the opening of transient pores in the lipid bilayer of endosome is involved (Melikov and 
Chernomordik 2005), alternatively CPPs may undergo conformational changes in response 
to the acidification inside the endosomes, leading to destabilization of the endosomal 
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membrane bilayer (Kichler, Mason et al. 2006). Last but not least, photochemical 
internalization (PCI) is a technique that aims to improve endosomal release. A 
photosensitizer is localized in the endosomal membrane and destabilizes the membrane 
upon illumination, triggering the release of endosomal content into cytosol (Berg, Kristian 
Selbo et al. 1999; Endoh and Ohtsuki 2009).  
In order to achieve high levels of transfection, different strategies have been employed to 
protect nucleic acids from degradation inside endosomes and facilitate their early release 
from acidic compartments into the cytosol. Various endosomal escape mechanisms of non-
viral vectors as well as the endosomolytic reagents which can promote endosomal release 
are introduced in detail here. 
2. Strategies of non-viral vectors for endosomal escape 
2.1. The ‘proton sponge’ hypotheses (pH-buffering effect) 
There is a long history regarding the application of cationic polymers to mediate nucleic 
acid transfer into cells. Cationic polymers can form polyplexes with nucleic acids through 
electrostatic interaction. Polylysine (PLL) was one of the first cationic polymers investigated 
for nucleic acid delivery although it failed to display desirable transfection efficiency (Pack, 
Hoffman et al. 2005). Later, it was discovered that polymers that contain protonable residues 
at physiological pH, like polyamidoamine (PAMAM) dendrimers and lipopolyamines 
(Remy, Sirlin et al. 1994) successfully achieve high transfection efficiency in contrast to PLL, 
which does not possess buffering capacity because of the presence of the strongly charged 
amino groups (Haensler and Szoka Jr 1993). This pH-buffering property was soon shown to 
be an important feature of cationic polymers that may induce endosomal disruption and 
prevent nucleic acids from lysosomal degradation.  
Polyethylenimine (PEI) is a synthetic cationic polymer with high amine density and various 
applications (Godbey, Wu et al. 1999). In 1995, Boussif et al. investigated the DNA delivery 
potential of PEI and found that this polymer can effectively transfer luciferase reporter gene 
into a variety of cell lines and primary cells (Boussif, Lezoualc'h et al. 1995). The remarkable 
nucleic acid-delivery ability of PEI was attributed to a “proton sponge” effect in which the 
extensive buffering capacity of PEI serves a dual purpose: (i) to inhibit the activity of 
lysosomal nuclease and (ii) to change the osmolarity of acidic vesicles resulting in 
endosomal swelling and rupture. 
The ‘proton sponge’ phenomenon has been observed in certain cationic polymers with a 
high pH buffering capability over a wide pH range. These polymers usually contain 
protonatable secondary and/or tertiary amine groups with pKa close to 
endosomal/lysosomal pH. During the maturation of endosomes, the membrane-bound 
ATPase proton pumps actively translocate protons from the cytosol into the endosomes, 
leading to the acidification of endosomal compartments and activation of hydrolytic 
enzymes. At this stage, polymers with the ‘proton sponge’ property will become protonated 
and resist the acidification of endosomes (fig. 1). As a result, more protons will be 
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continuously pumped into the endosomes with the attempt to lower the pH. The proton 
pumping action is followed by passive entry of chloride ions, increasing ionic concentration 
and leading to water influx. Eventually the osmotic pressure causes swelling and rupture of 
endosomes, releasing their contents to the cytosol (Boussif, Lezoualc'h et al. 1995; Behr 1997; 
Pack, Hoffman et al. 2005). Sonawane et al. (Sonawane, Szoka Jr et al. 2003) tested this 
hypothesis by studying the concentration of chloride ions, pH and the volume of endosomes 
after internalization of polyplexes composed of pDNA, non-buffering PLL as well as the 
highly buffering PEI and PAMAM. Significant chloride ion accumulation, volume 
expansion and membrane lysis were detected in PEI and PAMAM containing endosomes 
but not the ones with PLL. This finding provides direct support for the proton sponge 
hypothesis and a rationale for the design of polymer-based nucleic acid delivery vectors.  
 
Figure 1. The ‘proton sponge’ hypotheses (pH-buffering effect). (A) Polyplexes enter cell via 
endocytosis and are trapped in endosomes. (B) The membrane bound ATPase proton pumps actively 
translocate protons into endosomes. Polymers become protonated and resist the acidification of 
endosomes. Hence more protons will be pumped into the endosomes continuously to lower the pH.  
(C) The proton pumping action is followed by passive chloride ions entry, increasing ionic 
concentration and hence water influx. High osmotic pressure causes the swelling and rupture of 
endosomes, releasing their contents to cytosol. 
To date, PEI has been demonstrated to transfect nucleic acids successfully into a broad range 
of cells and tissues both in vitro and in vivo (Boletta, Benigni et al. 1997; Goula, Remy et al. 1998; 
Coll, Chollet et al. 1999; Urban-Klein, Werth et al. 2004; Merkel, Beyerle et al. 2009; Pfeifer, 
Hasenpusch et al. 2011). However, the clinical application of PEI is limited by its substantial 
toxicity. Chollet et al. (Chollet, Favrot et al. 2002) injected linear PEI (L-PEI) –pDNA polyplexes 
into mice intravenously. Signs of toxicity caused by L-PEI were observed 15 minutes after 
injection of 50 mg of L-PEI/DNA complexes. Increasing the dose up to 100 mg remarkably 
enhanced the transfection efficiency, but most of the animals suffered from liver necrosis. If the 
dose was increased to 150 mg, all the treated animals died of shock within the first 30 minutes. 
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Modified versions of PEI, such as low molecular weight PEI (LMW-PEI) (Kunath, von Harpe 
et al. 2003) and low branching degree PEI (Fischer, Bieber et al. 1999), have been investigated 
to reduce the toxicity of the polymers without compromising their pH buffering capacity 
(Kunath, von Harpe et al. 2003; Arote, Kim et al. 2007).  
On the contrary, polymeric carriers that do not possess pH buffering properties, such as 
chitosan and PLL, fail to achieve satisfactory nucleic acid delivery efficiencies because of 
their inability to induce endosomal escape even though they are capable of binding to 
nucleic acids and promoting cellular entry (Wagner and Kloeckner 2006). To enhance 
transfection efficiency, functional moieties were included into these polymeric systems for 
improving their buffering capacity. Histidine is one of the commonly employed molecules 
that was added as functional group of polymers or incorporated into peptide sequences to 
enhance their pH buffering capacity.  
The buffering capacity of histidine is due to the presence of an imidazole ring that has a pKa 
around 6 and hence can be protonated in a slightly acidic pH (Midoux, Pichon et al. 2009). 
Midoux et al. (Midoux and Monsigny 1999) reported that partial substitution of PLL with 
histidine residues resulted in transfection 4-5 orders of magnitude higher than the 
unmodified PLL/pDNA polyplexes. Upon protonation of the imidazole groups, the histidine 
residues trigger destabilization of polyplexes and fusion with endosomal membrane, 
leading to the release of polyplexes into cytosol. Chang et al. (Chang, Higuchi et al. 2010) 
introduced histidine to the amino groups of chitosan via disulfide bonds. The result showed 
that histidine-modified chitosan has a broader pH buffering range, wider distribution in the 
cytosol as well as a higher transfection level. It is evident that histidine can facilitate pDNA 
escape from endosomes by increasing the buffering capacity of chitosan inside the acidic 
compartments. A similar approach was adopted by other researchers to enhance other 
polycations by introducing imidazole moieties to enhance the pH buffering capacity and 
ultimately promote endosomal escape. (Yang, Lee et al. 2006; Moreira, Oliveira et al. 2009).  
2.2. Flip-flop mechanism 
Lipids and liposomes, whether anionic, cationic, neutral and/or pH-sensitive, present 
another category of non-viral carriers that have been extensively investigated for delivering 
nucleic acid into mammalian cells. In general, the in vitro and in vivo transfection efficiency 
of non-cationic lipids or liposomes is relatively low when compared with their cationic 
counterparts (Legendre and Szoka Jr 1992). Cationic lipids or liposomes form lipoplexes 
with the anionic nucleic acids through electrostatic interactions and the overall charge of the 
lipoplexes are usually positive so that they can easily associate with the negatively charged 
cell surface to promote cellular entry (Felgner, Gadek et al. 1987).  
The mechanism of how lipoplexes gain entry into the cells is controversial. According to 
literature, there are at least two routes of cellular uptake: (i) direct fusion with the plasma 
membrane; and (ii) endocytosis (Pedroso de Lima, Simões et al. 2001). Physicochemical 
properties of lipoplexes such as particle size distribution, lipid composition and charge ratio 
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may also influence their uptake route. In order to gain a better insight of the uptake 
mechanism of lipid-based system, Wrobel and Collins studied the interaction between 
cationic liposomes and model anionic membrane as well as cultured mammalian cells. The 
results indicated that cell surface binding alone is insufficient for cationic liposomes to gain 
entry into cells via membrane fusion in the absence of endocytosis (Wrobel and Collins 
1995). Zhou et al. investigated the DNA transfection of cationic liposomes containing 
lipopolylysine and found that only 2% of the treated cells were transfected and the uptake 
was mediated by membrane fusion (Zhou and Huang 1994). No correlation between fusion 
of the lipoplexes with the plasma membrane and the transfection level in monocytic THP-1 
cells was observed (Pires, Simões et al. 1999). Nevertheless, some investigators believed that 
membrane fusion is significant in the internalization of lipoplexes and the contribution of 
this uptake pathway cannot be completely ruled out.  
To find out the intracellular fate of the lipoplexes following endocytosis, an electron 
microscopic study was carried out by Zabner et al. (Zabner, Fasbender et al. 1995). It was 
observed that after cellular uptake, lipoplexes were delivered to perinuclear vesicular 
compartments which fuse with early endosomes. It was also noticed that the dissociation of 
nucleic acids from lipoplexes and their escape from endosomes are crucial barriers for 
successful transfection. To elucidate this endosomal escape mechanism of cationic 
liposomes, Zelphatl et al. identified the biomolecules that are responsible for dissociating of 
nucleic acids from the lipoplexes and releasing them into cytosol. Anionic liposomes with 
similar components with the cytoplasmic-facing monolayer of plasma membrane were used 
as an endosomal model. It was found that the anionic liposomes were able to trigger a rapid 
release of nucleic acid from lipoplexes. On the basis of this result, a ’flip-flop’ mechanism 
(fig. 2) was proposed by the authors to describe how nucleic acids were able to dissociate 
from the lipoplexes and escape from the endosomes into the cytosol (Zelphati and Szoka 
1996; Zelphati and Szoka 1996). Once inside the endosomes, there is an electrostatic 
interaction between the cationic lipoplexes and the negatively charged lipids (mainly found 
in the cytoplasmic-facing leaflet) of the endosomal membrane. The anionic lipids of the 
endosomal membrane laterally diffuse into the lipoplexes and form charge-neutralized ion 
pairs with the cationic lipids of the lipoplexes. As a result, the nucleic acids are displaced 
from the lipoplexes, allowing the nucleic acids to be released into the cytoplasm (Zhou and 
Huang 1994; Xu and Szoka Jr 1996; Zelphati and Szoka 1996).  
Neutral lipids such as the phosphatidylethanolamine (DOPE) are widely used as helper lipids 
in combination with cationic liposomes. It is well established that inclusion of DOPE in 
lipoplexes may significantly improve their transfection activity, whereas replacement of DOPE 
with other neutral phospholipid dioleoylphosphatidylcholine (DOPC) fails to accomplish the 
helper function. The role of DOPE as helper lipid is attributed to its endosomolytic activity. 
Zhou and Huang used transmission electron microscopy to study intracellular trafficking of 
cationic liposomes and found that DOPE-containing lipoplexes can destabilize the endosomal 
membrane (Zhou and Huang 1994) whereas the DOPC-containing lipoplexes did not show the 
same effect. A study carried out by Farhood et al. indicated that a substantial amount of DOPE 
needs to be incorporated into cationic liposomes in order to achieve endosomal membrane 
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destabilization (Farhood, Serbina et al. 1995). Both DOPE and DOPC share very similar acyl 
chain composition (Hui, Langner et al. 1996) and the major difference between the two 
phospholipids is their headgroups. The former has an ethanolamine head group whereas the 
latter contains a choline head group. The cone-shape ethanolamine head group of DOPE 
displays a high tendency to form inverted hexagonal phase especially at acidic pH while the 
choline head group of DOPC does not. Zuhorn et al. hypothesized that the formation of 
hexagonal phase of DOPE containing lipoplexes plays a prominent role both in dissociation of 
nucleic acids from lipoplexes and in efficient destabilizing endosomal membrane (Zuhorn, 
Bakowsky et al. 2005).  
 
Figure 2. Flip-Flop Mechanism. (A) Lipoplexes are endocytosed and become entrapped inside the early 
endosomes. (B) There is an electrostatic interaction between the cationic lipoplexes and the anionic 
lipids which are present in the cytoplasmic-facing side of endosomal membrane. The anionic lipids of 
the endosomal membrane laterally diffuse into the lipoplexes and form charge-neutralized ion pairs 
with the cationic lipids of the lipoplexes. (C) The nucleic acids are displaced from the lipoplexes, 
allowing the nucleic acids entry into the cytoplasm. 
Apart from helper lipids, other approaches have been investigated to potentiate endosomal 
lysis and the release of nucleic acid from lipoplexes to cytosol through the ‘flip-flop’ 
mechanism. Simoes et al. (Simoes, Slepushkin et al. 1999) described the use of the pH-
sensitive endosome-disruptive peptide, GALA, together with lipoplexes (more 
endosomolytic peptides will be discussed later). A significant improvement in transfection 
was observed in several cell types and the enhancement was blocked by bafilomycin A1, a 
specific inhibitor of the vacuolar ATPase proton pump that inhibits the acidification of the 
endosomes. Since low pH is a triggering factor of the membrane disruption propensity of 
GALA, the authors speculated that the membrane destabilizing activity of GALA involves 
structural changes of the peptide which induce the dissociation of nucleic acids from 
lipoplexes inside the endosomes. As a result, the dissociated cationic lipids become available 
to interact with the anionic lipids of the endosomal membrane more readily, leading to the 
release of nucleic acids into the cytosol via the ‘flip-flop’ mechanism. 
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2.3. Endosomal membrane fusion or destabilization mechanism 
Cell-penetration peptides (CPPs) have attracted tremendous attention as non-viral nucleic 
acid delivery vectors in recent years. Typically cationic and/or amphipathic in nature, CPPs 
are short sequences of amino acids, usually 10-30 residues, claimed to have ability to cross 
the plasma membrane of living cells. They can facilitate the transportation of various 
hydrophilic macromolecules including proteins, peptides and nucleic acids into cells 
without the disruption of plasma membrane (Richard, Melikov et al. 2003). CPPs were 
originally derived from viruses, with TAT peptide being the first CPP identified and was 
derived from the transcription activating factor of human immunodeficiency virus 1 (HIV-l) 
(Brooks, Lebleu et al. 2005). Many different sequences of CPPs were soon discovered and 
synthetic analogues were also rapidly developed. Until now there are a number of CPPs that 
were documented for nucleic acid delivery. 
CPPs either form complexes with nucleic acids, through electrostatic interaction, or can be 
incorporated into polymeric and lipidic delivery system. In general, they can be categorized 
into two main classes (Futaki 2006; Patel, Zaro et al. 2007): (i) Cationic peptides that usually 
contain arginine and lysine residues, e.g., TAT peptide, penetratin (Derossi, Joliot et al. 1994; 
Derossi, Calvet et al. 1996; Muratovska and Eccles 2004) and oligoarginines (Futaki 2006); (ii) 
Amphipathic peptides that consist of both hydrophobic and hydrophilic segments. The 
amphipathicity of these peptides generates from either the primary structure or the 
secondary structure. Primary amphipathic peptides are sequentially made up of 
hydrophobic and hydrophilic residues (Fernández-Carneado, Kogan et al. 2004; Deshayes, 
Morris et al. 2005), and include e.g., MPG (Simeoni, Morris et al. 2003; Veldhoen, Laufer et 
al. 2006), pep-1 and its analogues. Secondary amphipathic peptides adopt an amphipathic 
helical conformation with hydrophilic and hydrophobic regions and include e.g., HA-2 
(Wagner, Plank et al. 1992; Plank, Oberhauser et al. 1994), GALA (Li, Nicol et al. 2004), 
KALA (Wyman, Nicol et al. 1997), and LAH4 derivatives (Kichler, Leborgne et al. 2003; 
Kichler, Mason et al. 2006; Lam, Liang et al. 2012). The sequences and the endosomal escape 
mechanism of these peptides are summarized in table 1. In the past, it was generally 
accepted that a non-endosomal pathway or direct penetration was the major route of entry 
for CPPs (Morris, Chaloin et al. 2000). Early studies indicated that the uptake of CPPs into 
cells could progress at low temperature. It appeared to be energy-independent and 
insensitive to endocytosis inhibitors (Vivès, Brodin et al. 1997). However recent studies 
suggested otherwise, that endocytosis may actually be involved in the internalization of 
CPPs (Richard, Melikov et al. 2003; Lundin, Johansson et al. 2008). Until now, the uptake 
mechanism still remains controversial (Futaki 2005).  
Nevertheless, a variety of CPPs have been shown to enter cells via an endosomal pathway 
and induce endosomolytic activity. The majority of these membrane-destabilizing peptides 
were developed to mimic the endosomal disruptive properties of fusogenic sequences of 
viral fusion proteins. Taking the haemagglutin subunit HA2 of influenza virus as an 
example, this protein chain is responsible for facilitating membrane fusion. The C-terminal 
end is embedded in the viral membrane whereas the N-terminal end contains a fusion 
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peptide with a sequence of hydrophobic amino acids. Once inside the endosomes, HA 
undergoes conformation change in response to the low pH environment and expose the 
highly conserved hydrophobic N-terminal region. Subsequently, this triggers the fusion of 
viral membrane with the endosomal membrane, leading to viral genome leakage to cytosol 
(Stegmann 2000). Wagner et al. introduced HA2 as endosomolytic component in polyplexes 
containing transferrin/PLL/DNA, resulting in significantly augmentation of the delivery 
efficiency (Wagner, Plank et al. 1992). In contrast, peptides that are derived from HIV-1 
fusion protein gp41 usually adopt a pH-independent membrane fusion capacity and are 
capable of fusing with both plasma membranes and endosomes at neutral pH (Fischer, 
Krausz et al. 2001).  
Since the α-helical component of the HA2 appears to play a crucial role in endosomal 
membrane destabilization (Oehlke, Scheller et al. 1998), a series of pH-sensitive amphipathic 
α-helical structural motifs were designed and their structure–activity relationship were 
investigated. GALA is a synthetic peptide with 30 amino acid residues designed to interact 
with lipid bilayers at low pH. It contains a histidine and a tryptophan residue, as well as a 
glutamic acid-alanine-leucine-alanine (EALA) repeat. When the pH of the surrounding 
environment drops from 7.0 to 5.0, GALA experiences a conformational change from a 
random coil to an amphipathic α-helix, leading to disruption of model lipid membranes and 
therefore the release of entrapped aqueous content. The membrane-destabilizing character 
of this pH sensitive peptide in an acidic environment raises the possibility of enhancing the 
delivery of nucleic acid by facilitating endosomal escape (Li, Nicol et al. 2004). Haensler and 
Szoka Jr et al reported that when GALA is covalently attached to the dendrimer via a 
disulfide linkage, an increase of gene expression by 2-3 orders of magnitude was observed 
(Haensler and Szoka Jr 1993). Simoes’s study revealed that by incorporating GALA with 
transferrin containing lipoplexes, there was a significant increase in luciferase gene 
expression in COS-7 cells (Simoes, Slepushkin et al. 1999). Similarly, introducing GALA 
peptide into the multifunctional envelope-type nano device (MEND) can lead to 
improvement of nucleic acid transfer by facilitating nanoparticle endosomal escape (Sasaki, 
Kogure et al. 2008). 
The negatively charged GALA cannot bind with nucleic acid through electrostatic 
interaction, GALA can only be added as an additional functional component to polyplexes 
or lipoplexes. Newer peptides were soon developed to combine both nucleic acid binding 
and membrane destabilizing properties in order to produce a simpler delivery system. 
KALA is a modified version of GALA by partially replacing glutamic acid with lysine. It is 
one of the first generation peptides that is designed to bind nucleic acids as well as 
destabilize the endosomal membranes. Interestingly, the membrane destabilization 
mechanism of KALA is substantially different from that of GALA although they share 
similar amino acid sequence. KALA adopts α-helix conformation in a wide pH range and 
undergoes a pH-dependent conformational change from amphipathic α-helical to a mixture 
of α-helix and random coil as the pH is lowered (Wyman, Nicol et al. 1997). Apart from 
GALA and KALA, other amphipathic peptides that attain endosomal escape ability that is 
related to their α-helical structure include the Hel series peptides (Niidome, Takaji et al.  
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Peptide Primary Sequence Endosomal Escape 
Mechanism 
Reference 
TAT GRKKRRQRRRPPQ Unclear, endosomal 
escape is inefficient 
 
(Vives 2003; Brooks, 
Lebleu et al. 2005; 
Lee, Johnson  
et al. 2011) 
Penetratin RQIKIWFQNRRMKWKK Unclear, endosomal 
escape is inefficient 
 
(Muratovska  
and Eccles 2004) 
EBI LIRLWSHLIHIWFQNRRLKW
KKK 
Membrane 
destabilization 
(Lundberg,  
El-Andaloussi  
et al. 2007) 
MPG GALFLGFLGAAGSTMGAWS
QPKKKRKV 
 
Bypass endosomes 
through non-endosomal 
uptake 
(Morris, Vidal  
et al. 1997;  
Simeoni, Morris  
et al. 2003) 
HGP LLGRRGWEVLKYWWNLLQ
YWSQELC 
Membrane 
destabilization, possibly 
pore formation 
(Kwon, Bergen  
et al. 2008) 
Pep-2 KETWFETWFTEWSQPKKKR
KV 
Bypass endosomes 
through non-endosomal 
uptake 
(Morris, Depollier  
et al. 2001; Gros, 
Deshayes et al. 2006; 
Deshayes,  
Morris et al. 2008) 
HA-2 
derived 
fusogenic 
peptide 
GLFGAIAGFIEGGWTGMIDG
WYG 
Membrane fusion and 
destabilization 
(Wagner, Plank  
et al. 1992;  
Plank, Oberhauser  
et al. 1994;  
Navarro-Quiroga, 
Antonio González-
Barrios et al. 2002) 
H5WYG 
 
GLFHAIAHFIHGGWHGLIHG
WYG 
Membrane 
destabilization 
(Midoux, Kichler  
et al. 1998; 
Pichon, Gonçalves  
et al. 2001) 
INF-7 GLFEAIEGFIENGWEG 
MIDGWYG 
Membrane fusion and 
destabilization 
(Plank, Oberhauser 
et al. 1994;  
van Rossenberg, 
Sliedregt-Bol  
et al. 2002;  
Funhoff, van 
Nostrum et al. 2005) 
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Peptide Primary Sequence Endosomal Escape 
Mechanism 
Reference 
E5 & 
E5CA 
GLFGAIAGFIEGGWTGMIDG
 
GLFEAIAEFIEGGWEGLIEGC
A 
Membrane fusion and 
destabilization 
(Midoux, Mendes  
et al. 1993;  
Pichon, Freulon  
et al. 1997; 
Vliegenthart, 
Knollen et al. 1999; 
Klink, Chao  
et al. 2001) 
JTS-1 GLFEALLELLESLWELLLEA Membrane 
destabilization 
(Gottschalk, Sparrow 
et al. 1996; Fominaya, 
Gasset et al. 2000; 
van Rossenberg, 
Sliedregt-Bol  
et al. 2002; Vlasov, 
Lesina et al. 2005) 
ppTG1 GLFKALLKLLKSLWKLLLKA Membrane 
destabilization 
(Rittner, Benavente  
et al. 2002; Numata 
and Kaplan 2010) 
GALA WEAALAEALAEALAEHLAE
ALAEALEALAA 
Membrane 
destabilization, Pore 
formation & flip-flop of 
membrane lipids  
(Parente, Nir et al. 
1990; Haensler and 
Szoka Jr 1993; Fattal, 
Nir et al. 1994; Plank, 
Oberhauser  
et al. 1994; Simoes, 
Slepushkin  
et al. 1999;  
Li, Nicol et al. 2004) 
KALA WEAKLAKALAKALAKHLA
KALAKALKACEA 
Membrane 
destabilization 
(Wyman,  
Nicol et al. 1997;  
Li, Nicol et al. 2004;  
Min, Lee et al. 2006) 
CADY GLWRALWRLLRSLWRLLWR
A 
 
Bypass endosomes 
through non-endosomal 
uptake 
(Crombez, Aldrian-
Herrada et al. 2008) 
Peptide 46 
& 
analogues 
LARLLARLLARLLRALLRAL
LRAL 
 
Membrane 
destabilization 
(Niidome, Ohmori  
et al. 1997) 
HEL 
peptides & 
analogues 
KLLKLLLKLWKKLLKLLK Membrane 
destabilization 
(Ohmori, Niidome  
et al. 1998; Niidome, 
Takaji et al. 1999) 
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Peptide Primary Sequence Endosomal Escape 
Mechanism 
Reference 
LAH4 & 
analogues 
KKALLALALHHLAHLALHL
ALALKKA 
Membrane 
destabilization 
(Kichler, Leborgne  
et al. 2003; Kichler, 
Mason et al. 2006; 
Lam, Liang  
et al. 2012) 
Table 1. The sequences and the endosomal escape mechanism of selected CPPs that are being 
investigated for nucleic acid delivery. 
1999), INF 7 (Plank, Oberhauser et al. 1994), HGP (Kwon, Bergen et al. 2008), JTS-1 
(Gottschalk, Sparrow et al. 1996), EBI (Lundberg, El-Andaloussi et al. 2007), ppTG1 (Rittner, 
Benavente et al. 2002) and CADY (Crombez, Aldrian-Herrada et al. 2008; Konate, Crombez 
et al. 2010). 
The LAH4 peptide and its derivatives are another class of peptide that exhibits efficient gene 
transfer activity (Kichler, Leborgne et al. 2003; Lam, Liang et al. 2012). Peptides of the LAH4 
family are synthetic cationic amphipathic peptides containing a variable number of histidine 
residues and hydrophobic amino acids (mainly alanines and leucines). They were initially 
designed to investigate the interactions that determine the alignment of membrane-
associated proteins (Bechinger 1996; Vogt and Bechinger 1999). In vitro transfection 
experiments indicated that peptides with four to five histidine residues in the central region 
of the sequence achieved high transfection efficiency that is comparable to PEI. The 
transfection activity was significantly abolished in the presence of proton pump inhibitor 
bafilomycin A1, suggesting acidification is important for these peptides to mediate high 
transfection level. In a model membrane experiment, it was noticed that there was a 
preferential peptide-lipid interaction between LAH4 derivatives and anionic lipids, leading 
to the disruption of the lipid acyl chains in the acidic environment (Mason, Martinez et al. 
2006). Furthermore, LAH4 peptides experience a pH-dependent conformational change 
from transmembrane orientation at neutral pH to an in-plane orientation at low pH. The pH 
at which the conformation transition takes place is crucial and highly affects the transfection 
efficiency (Bechinger 1996; Vogt and Bechinger 1999; Kichler, Leborgne et al. 2003). Based on 
these observations, it was proposed that at neutral pH, LAH4 adopts a transmembrane 
orientation without disrupting the membrane integrity. During acidification of the 
endosomes, the imidazole groups of histidine residues become protonated and the peptide 
changes to an in-plane alignment and interact with the anionic lipids in the endosomal 
membrane. Membrane destabilization occurs, followed by the release of nucleic acid into the 
cytosol (Kichler, Mason et al. 2006). 
2.4. Pore formation 
Pore formation is another mechanism to explain the endosomal escape of peptide-based 
nucleic acid delivery systems. Parente et al. (Parente, Nir et al. 1990) investigated content-
leaking kinetics of peptide GALA from phospholipid vesicles over a wide range of pH. As 
 
Molecular Regulation of Endocytosis 442 
previously mentioned, GALA undergoes a pH-dependent conformational change to give a 
helical structure at acidic environment. It was suggested that leakage from phospholipid 
vesicles is promptly initiated by low pH (pH＜6) and is rapidly terminated when the pH is 
raised to 7.5. The author assumes that GALA becomes incorporated into the vesicle bilayer 
and aggregates to form a pore with diameter ranges from 5 to 10 Å. Fattal et al. further 
investigated the mechanism of pore-forming peptides GALA in details. They concluded that 
pore formation is a key event that may result in phospholipid flip-flop of biological 
membranes, leading to the releasing of contents (Fattal, Nir et al. 1994). Simoes et al. (Simoes, 
Slepushkin et al. 1999) combined GALA with lipoplexes and found significant improvement 
of transfection in several cell cells. The results indicated that the cellular uptake of lipoplexes 
is though endocytosis and the endosomal escape play a crucial role in intracellular delivery 
of lipoplexes. However, the authors believe that the dimension of the pores (5 to 10 Å) 
formed by this peptide may not be big enough to permit the escape of nucleic acid from 
endosomes. Multiple mechanisms may be accounted for the enhancement of transfection 
efficiency, including structural changes of the peptide, facilitation of nucleic acid 
dissociation from the lipoplexes and the flip-flop mechanism.  
2.5. Photochemical internalization (PCI) 
Photochemical internalization (PCI) is a light-directed delivery technology that utilizes 
photosensitizers to facilitate the transport of membrane impermeable macromolecules from 
endocytic vesicles into cytoplasm. The mechanism of PCI as an endosomal escape enhancer 
strategy is very straight-forward (Fig.3). Photosensitizers that are employed in the PCI 
technology are usually amphiphilic compounds which can bind to and localize in the 
plasma membrane. After being taken up by the cells through endocytosis, the 
photosensitizers are confined to the endosomal membranes and remain inactive until 
triggered by light with specific wavelengths matching their absorption spectra (Selbo, 
Weyergang et al. 2010). Once activated, they induce the formation of highly reactive oxygen 
species, mainly singlet oxygen, leading to the rupture of endosomes and lysosomes 
membrane. As a result, macromolecules that are trapped inside the endosomes/lysosomes 
can be liberated into the cytosol (Berg, Kristian Selbo et al. 1999). Photosensitizers used in 
clinical application are highly reactive reagents with short range of action (10-20 nm) and 
short life-time (0.01-0.04 μs), thus restricting the damaging effect to the production site 
(within the endosomal membrane) without affecting other cellular components (Moan and 
Berg 1991; Berg, Weyergang et al. 2010). Most of the photosensitizers do not localize to the 
nucleus of the cells, thereby reducing the possibility of causing any mutagenic effects 
(Dougherty, Henderson et al. 1998). 
PCI was initially investigated for anti-tumour drug delivery. A synergistic effect of 
combining PCI with chemotherapeutic agents was found. PCI principally targets cellular 
endocytosis that may affect the distribution of molecules that are taken up by the cells via 
endosomal pathway. It was later employed as a tool to improve the cellular delivery of a 
large variety of bioactive macromolecules and nucleic acids including pDNA, siRNA and 
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oligonucleotides (Selbo, Weyergang et al. 2010). Examples of photosensitizers that are used 
in non-viral nucleic acid delivery including disulfonated meso-tetraphenylporphine (TPPS2a) 
(Prasmickaite, Høgset et al. 2000; Kloeckner, Prasmickaite et al. 2004; Maurice-Duelli, Ndoye 
et al. 2004; Ndoye, Merlin et al. 2004; Ndoye, Dolivet et al. 2006; Oliveira, Fretz et al. 2007; 
Boe, Longva et al. 2008; Raemdonck, Naeye et al. 2009; Bøe, Sæbøe-Larssen et al. 2010), 
disulfonated aluminium phthalocyanine (AlPcS2a) (Berg, Prasmickaite et al. 2003; Hellum, 
Høgset et al. 2003; Ndoye, Dolivet et al. 2006; Yip, Weyergang et al. 2007), Zinc-
phthalocyanine (Zn-Pc) dendrimer (Nishiyama, Iriyama et al. 2005; Arnida, Nishiyama et al. 
2006) and 5,10,15-tri(4-acetamidophenyl)-20-mono(4-carboxyl-phenyl)porphyrin (TAMCPP) 
conjugated to G4 PAMAM dendrimer (Shieh, Peng et al. 2008). 
 
Figure 3. The mechanism of photochemical internalization technology. (A) Photosensitizers bind to and 
localize in the plasma membrane. (B) Photosensitizers can be taken up by the cells through endocytosis 
with the delivery systems. (C) Photosensitizers are confined to the endosomal membrane and remain 
inactive. (D) Photosensitizers are activated by illumination and induce the formation of highly reactive 
oxygen species, leading to the rupture of endosomes /lysosomes membrane. (E) Molecules that are 
trapped inside the endosomes/lysosomes can be liberated into the cytosol. 
To employ PCI in clinical applications, the penetration of light into the deep tissue is an 
important issue (Oliveira, Fretz et al. 2007). With the development of fiber optics and laser 
technology, the control of illumination to sites that are deep inside the human body becomes 
possible, e.g. gastrointestinal tract, urogenital organs, lungs, brain and pancreas (Dougherty, 
Henderson et al. 1998; Chatterjee, Fong et al. 2008). PCI mediated therapy can be used in 
many regions of the body where light delivery can be achieved and where local activation of 
a drug is desirable. A photosensizer is injected as a single dose prior to light activation. 
Parameters such as the dose of photosentizers and light, as well as the time interval between 
administration of photosentiziers and drugs must be carefully optimized. In vivo 
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experiments demonstrated that PCI, in combination with a chemotherapeutic agent, has a 
good effect on cancer treatment (Selbo, Sivam et al. 2001; Berg, Dietze et al. 2005; Hirschberg, 
Zhang et al. 2009; Norum, Gaustad et al. 2009). In the field of nucleic acid delivery, it has 
been shown that PCI was able to transfer pDNA and siRNA into cytosol efficiently to 
enhance their biological effects in vitro. Only a number of in vivo studies have been carried 
out to demonstrate the feasibility of PCI technology to enhance the delivery of pDNA to 
conjunctival tissue (Nishiyama, Iriyama et al. 2005) and tumour tissues (Ndoye, Dolivet et 
al. 2006), as well as the delivery of siRNA to a tumour site (Oliveira, Hogset et al. 2008). The 
result was very promising. Perhaps more effort should be invested to further develop this 
technology for clinical use. 
2.6. Other endosomal escape mechanisms 
Exogenous additives, such as chloroquine and inactivated adenovirus, have been exploited 
to promote endosomal escape and enhance the efficiency of nucleic acid delivery. 
Chloroquine is a weak base that can rapidly penetrate the plasma membrane, accumulate in 
acidic vesicles and increase the pH of the acidic compartment (Maxfield 1982; Mellman, 
Fuchs et al. 1986). Preventing endosome acidification may subsequently inhibit hydrolytic 
enzymes such as proteases and nucleases (Cotten, Längle-Rouault et al. 1990). Chloroquine 
also causes the swelling and rupture of endosomal vesicle by increasing the osmotic 
pressure inside the acidic compartment (Khalil, Kogure et al. 2006). Since it can neutralize 
acidic compartment and induce rupture of endocytic vesicles, adding chloroquine is an 
alternative measure to improve nucleic acid transfer (Erbacher, Roche et al. 1996).  
A number of early studies found that chloroquine is able to enhance DNA transfection in 
various cell types (Luthman and Magnusson 1983; Cotten, Längle-Rouault et al. 1990; 
Erbacher, Roche et al. 1996). Chloroquine promotes escape of polyplexes or lipoplexes from 
endosome via increasing endosomal pH and hindering endosome fusion with lysosome. To 
date, chloroquine has been widely used to elucidate the uptake mechanism of non-viral 
nucleic acid delivery systems (Legendre and Szoka Jr 1992; Simeoni, Morris et al. 2003; 
Lehto, Abes et al. 2010). However, it is worth noting that chloroquine does not always lead 
to an improvement of transfection efficiency, depending on the uptake pathway of the 
delivery systems. Haensler and Szoka reported that transfection of PAMAM was not 
affected by the presence of chloroquine (Haensler and Szoka Jr 1993). The authors suggested 
the endosomal lysis activity of PAMAM is strong enough to allow liberation of its content to 
cytosol with and without the presence of chloroquine. Legendre and Szoka (Legendre and 
Szoka Jr 1992) described an increase in transfection efficiency after chloroquine was added 
to DOTMA/DOPE liposomes. Interestingly, chloroquine exerts a negative effect on 
carcinoma cells transfected by DOPE/CHEMS pH-sensitive liposomes. The authors 
explained that the membrane destabilization activity of pH-sensitive liposome is attenuated 
when the acidic environment of endosome is perturbed by chloroquine. Transfection is a 
complicated process involving multiple steps, such as cellular binding, internalization and 
nuclear transport (in the case of DNA delivery). Apart from endosomal escape, other factors 
may also affect the eventual transfection efficiency.  
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Besides chloroquine, physically coupling chemically inactivated adenovirus particles is 
another approach for promoting endosomal escape. This method takes the advantage of the 
endosomolytic activity of adenovirus to facilitate the release of nucleic acids from the 
endosomes (Curiel, Agarwal et al. 1991; Cotten, Wagner et al. 1992; Wagner, Zatloukal et al. 
1992). Curiel et al. explored the application of adenovirus as an endosome disruption agent. 
The inactivated adenoviruses were coupled with transferring-polyplexes. It was observed 
that pDNA delivery into HeLa cells was improved 1000-fold or more when replication-
defective adenovirus particles were present (Curiel, Agarwal et al. 1991).  
However, the application of both chloroquine and inactivated adenovirus particles are 
limited due to safety concern. Although chloroquine is approved by the FDA as an anti-
malaria medication, it is found to be toxic to many cell types and can trigger 
gastrointestinal and nervous adverse effects in high dose (Pack, Putnam et al. 2000). For 
defective adenovirus particles, the complexity of vector production and potential 
immunogenicity raised by the virus components make this strategy problematic (Pack, 
Hoffman et al. 2005). Unless the safety issues can be solved, both methods will remain 
unsuitable for clinical use. 
3. Conclusion  
Non-viral vectors are considered to be promising vehicles for delivering therapeutic nucleic 
acids because of their relatively safe profile and high versatility as compared to their viral 
counterparts. However, the transfection efficiency of non-viral vectors is less than 
satisfactory for clinical purpose. The endocytosis pathway is a major route for the cellular 
entry of non-viral nucleic acid delivery agents. Poor endosomal escape of non-viral systems 
pose a major challenge for the intracellular delivery of nucleic acids. An ideal nucleic acid 
delivery system should fulfill several criteria: negligible toxicity, biocompatible and 
biodegradable, offer protection to nucleic acids from enzymatic degradation, facilitate 
cellular uptake, promote endosomal escape and release the nucleic acids at site of action. 
Elucidation of the mechanism of endosomal escape is beneficial in the development of more 
effective non-viral delivery vectors. However, the uptake and cytoplasmic transportation 
mechanisms of a variety of non-viral nucleic acid carriers still need to be investigated in 
more detail. In the future, with the development of cell imaging techniques such as high 
resolution, spinning disk live cell confocal imaging and the fluorescence correlation 
spectroscope, the details of intracellular trafficking of non-viral nucleic acid delivery 
systems will be unveiled. This will guide the future design and development of novel 
efficient non-viral nucleic acid delivery vectors.  
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